文献速递冠心病肺血管病与心包/心肌炎血脂与心血管预防

蛋白基因组数据整合揭示CXCL10是IL-6信号促动脉粥样硬化的潜在下游因果介质

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis.
PubMed 文献 · Circulation · 2023-12-28

BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response.…

要点

  • 遗传代理的IL-6信号抑制显著影响70种循环蛋白,与药物IL-6R抑制的蛋白效应相关。
  • CXCL10遗传代理水平与冠心病、大动脉粥样硬化性卒中和外周动脉疾病风险相关。
  • IL-6信号下调对这些终点的效应中高达67%由CXCL10降低所介导。

核心结论

  • 整合多组学数据发现IL-6信号激活的蛋白特征及其心血管病效应介质。
  • 干扰素-γ诱导趋化因子CXCL10可能是三个血管区域动脉粥样硬化的潜在因果介质。
  • CXCL10有望成为动脉粥样硬化保护的药物靶点。

研究设计与样本

  • 采用孟德尔随机化在INTERVAL队列3301人中评估对3281种血浆蛋白的效应。
  • 采用中介孟德尔随机化探索蛋白组学介质对冠心病、大动脉粥样硬化性卒中和外周动脉疾病的效应。
  • 在基于人群的研究(n=1704)中检验显著介质循环水平与 incident 心血管事件的关联,并在人动脉粥样硬化病变样本中探索组织学、转录组和细胞表型。

主要发现

  • 遗传代理的IL-6信号对70种参与细胞因子产生/调节和免疫细胞招募/分化的循环蛋白有显著效应,并与临床试验中药物IL-6R抑制的蛋白效应相关。
  • 在70种显著蛋白中,遗传代理的CXCL10循环水平与冠心病、大动脉粥样硬化性卒中和外周动脉疾病风险相关。
  • 遗传下调IL-6信号对这些终点的效应中高达67%由CXCL10降低所介导。
  • 较高的中年期循环CXCL10水平与20年内更多心血管事件相关。
  • 人动脉粥样硬化病变中较高的CXCL10表达与更大的脂质核心及反映免疫细胞浸润、适应性免疫系统激活和细胞因子信号的转录组谱相关。

关键数值与推荐

  • 遗传工具包含IL-6R基因26个变异,代理药物性IL-6R抑制。
  • 孟德尔随机化评估3281种血浆蛋白,样本为INTERVAL队列3301人。
  • 中介孟德尔随机化显示CXCL10介导高达67%的IL-6信号下调对三个血管终点的效应。
  • 人群研究样本n=1704,评估循环CXCL10水平与20年心血管事件关联。

临床怎么用

  • CXCL10可作为动脉粥样硬化保护的潜在药物靶点,支持进一步开发特异性干预。
  • 评估IL-6信号抑制的心血管获益时,可考虑CXCL10介导的通路作为疗效标志或替代靶点。
  • 循环CXCL10水平可能有助于识别IL-6信号相关心血管风险较高的个体。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects. METHODS: Leveraging data from 522 681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6R (IL-6 receptor) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization, we assessed its effects on 3281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3301). Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease. For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions. RESULTS: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 (C-X-C motif chemokine ligand 10) were associated with risk of coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease, with up to 67% of the effects of genetically downregulated IL-6 signaling on these end points mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher CXCL10 expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling. CONCLUSIONS: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Prapiadou S, Živković L, Thorand B, et al. Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis. Circulation. 2023. PMID: 38152968. doi:10.1161/CIRCULATIONAHA.123.064974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。